Suraksha Diagnostic Limited — PPTs, 09-08-2025: Investor Presentation

Here's a summary for retail investors:

**1. Financial Highlights:**

Suraksha Diagnostic reported robust Q1 FY26 financials: Total revenue hit ₹73.5 Cr (+19% YoY), EBITDA reached ₹24.7 Cr (+14% YoY) at a 34.0% margin, and PAT grew 20% YoY to ₹9.2 Cr (12.6% margin). Revenue per patient was ₹2,101.

**2. Strategic Initiatives & Business Developments:**

The company acquired a 63% stake in Fetomat Wellness in April 2025, integrating fetal medicine expertise. They also launched Suraksha Genomics, a new genetic testing vertical, with significant planned investments. Future strategy includes organic/inorganic expansion in Eastern/North-Eastern India and boosting B2B partnerships.

**3. Market Position & Competitive Advantage:**

As East India's largest integrated diagnostic chain, Suraksha leverages an "underserved" market with high growth potential. Its hub-and-spoke model, NABL-accredited labs, diversified revenue (Pathology 49%, Radiology 47%, OPD 4%), and IT infrastructure provide a strong competitive edge.

**4. Investor Implications:**

Solid Q1 results and strategic ventures (Fetomat acquisition, Genomics launch) indicate positive growth potential. Monitoring execution of expansion and technology investments in this high-growth Eastern Indian market will be key. #Healthcare #Diagnostics #Investment